Targeting MYCN and ALK in resistant and relapsing neuroblastoma

Abstract

Neuroblastoma, a tumor of peripheral nerve, is the most common solid tumor of young children. In high-risk disease, which comprises approximately half of patients, death from chemotherapy-resistant, metastatic relapse is very frequent. Children who relapse exhibit clonal enrichment of two genomic alterations: high-level amplification of the MYCN oncogene, and kinase domain mutations of the anaplastic lymphoma kinase (ALK) gene. Overall survival in this patient cohort is less than 15% at 3 years, and there are few options for rationally targeted therapy. Neuroblastoma patients exhibit de novo resistance to many existing ALK inhibitors, and no clinical therapeutics to target MYCN have yet been developed. This review outlines the international efforts to uncover mechanisms of oncogenic action that are therapeutically targetable using small-molecule inhibitors. We describe a mechanistic interaction in which ALK upregulates MYCN transcription, and discuss clinical trials emerging to develop transcriptional inhibitors of MYCN, and to identify effective inhibitors of ALK in neuroblastoma patients.

Keywords

Neuroblastoma / anaplastic lymphoma kinase / MYCN / therapeutics

References

[1] Morgenstern DA,Moreno L,Owens C.Risk stratification of high-risk metastatic neuroblastoma: a report from the HR-NBL-1/SIOPEN study..Pediatr Blood Cancer2018;65:e27363

[2] Bresler SC,Huwe PJ,Krytska K.ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma..Cancer Cell2014;26:682-94 PMCID:PMC4269829

[3] De Brouwer S,Kumps C,Porcu M.Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification..Clin Cancer Res2010;16:4353-62

[4] Basta NO,Makin G,Feltbower R.Factors associated with recurrence and survival length following relapse in patients with neuroblastoma..Br J Cancer2016;115:1048-57 PMCID:PMC5117794

[5] Barone G,Pearson AD,Chesler L.New strategies in neuroblastoma: therapeutic targeting of MYCN and ALK..Clin Cancer Res2013;19:5814-21 PMCID:PMC3818140

[6] Chesler L,Goldenberg DD,Kim G.Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma..Cancer Res2006;66:8139-46 PMCID:PMC2924674

[7] Vaughan L,Barker K,Gustafson CW.Inhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumors..Oncotarget2016;7:57525-44 PMCID:PMC5295370

[8] Smith JR,Heaton SP,Pearson AD.Novel pharmacodynamic biomarkers for MYCN protein and PI3K/AKT/mTOR pathway signaling in children with neuroblastoma..Mol Oncol2016;10:538-52 PMCID:PMC5423144

[9] Buchel G,Mak KY,Leen E.Association with aurora-A controls N-MYC-dependent promoter escape and pause release of RNA polymerase II during the cell cycle..Cell Rep2017;21:3483-97 PMCID:PMC5746598

[10] Brockmann M,Berry T,Deubzer HE.Small molecule inhibitors of aurora-a induce proteasomal degradation of N-myc in childhood neuroblastoma..Cancer Cell2013;24:75-89 PMCID:PMC4298657

[11] Gustafson WC,Nekritz EA,Benes C.Drugging MYCN through an allosteric transition in Aurora kinase A..Cancer Cell2014;26:414-27 PMCID:PMC4160413

[12] Otto T,Brockmann M,Schuttrumpf L.Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma..Cancer Cell2009;15:67-78

[13] DuBois SG,Fox E,Reid JM.Phase I study of the aurora A kinase inhibitor alisertib in combination with irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma: a NANT (new approaches to neuroblastoma therapy) trial..J Clin Oncol2016;34:1368-75 PMCID:PMC4872349

[14] DuBois SG,Fox E,Reid JM.Phase II trial of alisertib in combination with irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma..Clin Cancer Res2018;24:6142-9 PMCID:PMC6295246

[15] Moreno L,Geoerger B,Schleiermacher G.Accelerating drug development for neuroblastoma - new drug development strategy: an innovative therapies for children with cancer, European network for cancer research in children and adolescents and international society of paediatric oncology Europe neuroblastoma project..Expert Opin Drug Discov2017;12:801-11

[16] Mosse YP,Teachey DT,Safgren SL.A phase II study of alisertib in children with recurrent/refractory solid tumors or leukemia: children’s oncology group phase I and pilot consortium (ADVL0921)..Clin Cancer Res2019;25:3229-38

[17] Moreno L,Pearson AD,Elliott M.A phase I trial of AT9283 (a selective inhibitor of aurora kinases) in children and adolescents with solid tumors: a Cancer Research UK study..Clin Cancer Res2015;21:267-73

[18] Durbin AD,Dharia NV,Iniguez AB.Selective gene dependencies in MYCN-amplified neuroblastoma include the core transcriptional regulatory circuitry..Nat Genet2018;50:1240-46 PMCID:PMC6386470

[19] Puissant A,Alexe G,Qi J.Targeting MYCN in neuroblastoma by BET bromodomain inhibition..Cancer Discov2013;3:308-23 PMCID:PMC3672953

[20] Yang Z,Zhou Q.Brd4 recruits P-TEFb to chromosomes at late mitosis to promote G1 gene expression and cell cycle progression..Mol Cell Biol,2008;28:967-76 PMCID:PMC2223388

[21] Loven J,Lin CY,Orlando DA.Selective inhibition of tumor oncogenes by disruption of super-enhancers..Cell2013;153:320-34 PMCID:PMC3760967

[22] Henssen A,Odersky A,Koche R.Targeting MYCN-driven transcription by BET-bromodomain inhibition..Clin Cancer Res2016;22:2470-81

[23] Chipumuro E,Christensen CL,Zhang T.CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer..Cell2014;159:1126-39 PMCID:PMC4243043

[24] Lucking U,Lienau P,Kosemund D.Identification of atuveciclib (BAY 1143572), the first highly selective, clinical PTEFb/CDK9 inhibitor for the treatment of cancer..ChemMedChem,2017;12:1776-93 PMCID:PMC5698704

[25] Walton MI,Hayes A,De Haven Brandon AK.CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugs..Clin Cancer Res2012;18:5650-61 PMCID:PMC3474704

[26] Dolman ME,Ebus ME,van Noesel CJ.Cyclin-dependent kinase inhibitor AT7519 as a potential drug for MYCN-dependent neuroblastoma..Clin Cancer Res,2015;21:5100-9 PMCID:PMC4645454

[27] Ham J,Sano R,Sennott EM.Exploitation of the apoptosis-primed state of MYCN-amplified neuroblastoma to develop a potent and specific targeted therapy combination..Cancer Cell2016;29:159-72 PMCID:PMC4749542

[28] Wang H,Li X,Li H.JQ1 synergizes with the Bcl-2 inhibitor ABT-263 against MYCN-amplified small cell lung cancer..Oncotarget2017;8:86312-24 PMCID:PMC5689687

[29] Mosse YP,Longo L,Wood A.Identification of ALK as a major familial neuroblastoma predisposition gene..Nature2008;455:930-5 PMCID:PMC2672043

[30] Janoueix-Lerosey I,Brugieres L,de Pontual L.Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma..Nature2008;455:967-70

[31] Mosse YP,Voss SD,Ruffner K.Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children’s Oncology Group phase 1 consortium study..Lancet Oncol2013;14:472-80 PMCID:PMC3730818

[32] Chen Y,Choi YL,Ohira M.Oncogenic mutations of ALK kinase in neuroblastoma..Nature2008;455:971-4

[33] George RE,Hanna M,Luther W2nd.Activating mutations in ALK provide a therapeutic target in neuroblastoma..Nature2008;455:975-8 PMCID:PMC2587486

[34] Berry T,Bhatnagar N,Poon E.The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma..Cancer Cell2012;22:117-30 PMCID:PMC3417812

[35] Zhu S,Guo F,Perez-Atayde AR.Activated ALK collaborates with MYCN in neuroblastoma pathogenesis..Cancer Cell2012;21:362-73 PMCID:PMC3315700

[36] Umapathy G,Witek B,Danielson L.The kinase ALK stimulates the kinase ERK5 to promote the expression of the oncogene MYCN in neuroblastoma..Sci Signal2014;7:ra102

[37] Tucker ER,Danielson LS,Jamin Y.Immunoassays for the quantification of ALK and phosphorylated ALK support the evaluation of on-target ALK inhibitors in neuroblastoma..Mol Oncol2017;11:996-1006 PMCID:PMC5537911

[38] Guan J,Siaw JT,Van den Eynden J.Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinib..Cold Spring Harb Mol Case Stud2018;4: PMCID:PMC6071567

[39] Bresler SC,Haglund EA,Belcastro LT.Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma..Sci Transl Med,2011;3:108ra114 PMCID:PMC3319004

[40] Guan J,Wan H,Danielson LS.The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN..Dis Model Mech2016;9:941-52 PMCID:PMC5047689

[41] Infarinato NR,Krytska K,Sano R.The ALK/ROS1 inhibitor PF-06463922 overcomes primary resistance to crizotinib in ALK-driven neuroblastoma..Cancer Discov2016;6:96-107 PMCID:PMC4707106

[42] Johnson TW,Bailey S,Burke BJ.Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(m etheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations..J Med Chem2014;57:4720-44

[43] Heath JA,Thomas A.Good clinical response to alectinib, a second generation ALK inhibitor, in refractory neuroblastoma..Pediatr Blood Cancer2018;65:e27055

[44] Pacenta HL.Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma..Drug Des Devel Ther2018;12:3549-61 PMCID:PMC6204873

[45] Lambertz I,Claeys S,Beckers A.Upregulation of MAPK negative feedback regulators and RET in mutant ALK neuroblastoma: implications for targeted treatment..Clin Cancer Res2015;21:3327-39

[46] Krytska K,Sano R,Infarinato NR.Crizotinib Synergizes with chemotherapy in preclinical models of neuroblastoma..Clin Cancer Res2016;22:948-60 PMCID:PMC4755925

[47] Carr-Wilkinson J,Wood KM,Baker AG.High frequency of p53/MDM2/p14ARF pathway abnormalities in relapsed neuroblastoma..Clin Cancer Res2010;16:1108-18 PMCID:PMC2842933

[48] Yoda S,Lawrence MS,Friboulet L.Sequential ALK inhibitors can select for lorlatinib-resistant compound ALK mutations in ALK-positive lung cancer..Cancer Discov2018;8:714-29 PMCID:PMC5984716

[49] Shaw AT,Leshchiner I,Bergqvist S.Resensitization to crizotinib by the lorlatinib ALK resistance mutation L1198F..N Engl J Med2016;374:54-61 PMCID:PMC4773904

[50] Debruyne DN,Sharma B,Moore NF.ALK inhibitor resistance in ALK(F1174L)-driven neuroblastoma is associated with AXL activation and induction of EMT..Oncogene2016;35:3681-91 PMCID:PMC4885798

[51] Redaelli S,Zappa M,Mastini C.Lorlatinib treatment elicits multiple on- and off-target mechanisms of resistance in ALK-driven cancer..Cancer Res2018;78:6866-80

[52] Padovan-Merhar OM,Ostrovnaya I,Rubnitz KR.Enrichment of targetable mutations in the relapsed neuroblastoma genome..PLoS Genet2016;12:e1006501 PMCID:PMC5172533

[53] Chen L,Turnbull L,Schleiermacher G.Identification of different ALK mutations in a pair of neuroblastoma cell lines established at diagnosis and relapse..Oncotarget2016;7:87301-11 PMCID:PMC5349989

[54] Eleveld TF,Bernard V,Colmet Daage L.Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations..Nat Genet2015;47:864-71 PMCID:PMC4775079

[55] Schleiermacher G,Bernard V,Cappo J.Emergence of new ALK mutations at relapse of neuroblastoma..J Clin Oncol2014;32:2727-34

[56] Umapathy G,Gustafsson DE,Cervantes-Madrid D.MEK inhibitor trametinib does not prevent the growth of anaplastic lymphoma kinase (ALK)-addicted neuroblastomas..Sci Signal,2017;10:

[57] Wood AC,Ryles HT,Sano R.Dual ALK and CDK4/6 inhibition demonstrates synergy against neuroblastoma..Clin Cancer Res2017;23:2856-68 PMCID:PMC5457336

[58] Moore NF,Bhatnagar N,Drake LE.Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma..Oncotarget2014;5:8737-49 PMCID:PMC4226718

[59] Schonherr C,Kamaraj S,Yang HL.Anaplastic lymphoma kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells..Oncogene2012;31:5193-200

[60] Claeys S,Durinck K,Mus LM.ALK positively regulates MYCN activity through repression of HBP1 expression..Oncogene2019;38:2690-705

[61] Escamilla-Powers JR,Farrell A,Zhang X.The tumor suppressor protein HBP1 is a novel c-myc-binding protein that negatively regulates c-myc transcriptional activity..J Biol Chem2010;285:4847-58 PMCID:PMC2836090

[62] Watts E,Tucker E,Strebhardt K.Designing dual inhibitors of anaplastic lymphoma kinase (ALK) and bromodomain-4 (BRD4) by tuning kinase selectivity..J Med Chem2019;62:2618-37 PMCID:PMC6421522